Argenx Se (ARGX) Total Non-Current Liabilities (2016 - 2026)
Argenx Se's (ARGX) quarterly Total Non-Current Liabilities came in at $40.0 million in Q2 2026, down 99.89% on a YoY basis from $37.9 billion in Q2 2025, and up 2.56% quarter-over-quarter from $39.0 million in Q4 2025.
Analysis
Argenx Se (ARGX) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Total Non-Current Liabilities for 11 consecutive years, with $40.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Non-Current Liabilities fell 99.89% year-over-year to $40.0 million; the trailing twelve-month figure through Jun 2026 stood at $40.0 million (down 99.89% YoY), and the FY2025 full-year result was $39.0 million, down 99.89% from the prior year.
- Total Non-Current Liabilities grew to $40.0 million in Q2 2026 per ARGX's latest filing, from $39.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $37.9 billion in Q2 2025 and bottomed at $14.4 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $10.1 billion across 5 years, with a median of $39.0 million in 2025.
- The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities soared 156212.05% in 2024, then slumped 99.89% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $18.3 billion in 2022, then tumbled by 99.88% to $22.0 million in 2023, then jumped by 156212.05% to $34.3 billion in 2024, then sank by 99.89% to $39.0 million in 2025, then increased by 2.56% to $40.0 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $40.0 million, $39.0 million, and $37.9 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.17 Bn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | 739.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40.00 Mn |
| Dec 31, 2025 | 39.00 Mn |
| Jun 30, 2025 | 37.94 Bn |
| Dec 31, 2024 | 34.32 Bn |
| Jun 30, 2024 | 34.68 Mn |
| Dec 31, 2023 | 21.96 Mn |
| Jun 30, 2023 | 17.95 Mn |
| Dec 31, 2022 | 18.29 Bn |
| Jun 30, 2022 | 14.42 Mn |
| Dec 31, 2021 | 14.81 Bn |
| Jun 30, 2021 | 17.05 Mn |
| Dec 31, 2020 | 267.56 Bn |
| Jun 30, 2020 | 228.32 Mn |
| Dec 31, 2019 | 246.43 Mn |
| Jun 30, 2019 | 271.20 Mn |
| Dec 31, 2018 | 7,989.77 |
| Jun 30, 2018 | 29,836.11 |
| Dec 31, 2017 | 1.72 Mn |
| Jun 30, 2017 | 1,099.55 |
| Dec 31, 2016 | 1,087.39 |